Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 25;13(7):1894.
doi: 10.3390/jcm13071894.

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Jose María Mostaza  1 , Carlos Escobar  2
Affiliations
Review

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Jose María Mostaza et al. J Clin Med. .

Abstract

Vascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis. Therefore, reducing LDL cholesterol (LDL-C) to the goals recommended by clinical practice guidelines, is essential to decrease the risk of vascular complications. Despite this, current LDL-C control is scarce, even in subjects with high and very high risk. This is mainly due to an insufficient intensification of lipid-lowering treatment. In this context, it is essential to prescribe the appropriate therapy, adjusted to patient's needs based on their LDL-C and their vascular risk. Rosuvastatin, alone or in combination with ezetimibe, provides intensive LDL-C reductions (up to 50-55% and 60-75%, respectively), with a low risk of side effects and in an efficient manner, in patients both without and with established atherosclerotic vascular disease.

Keywords: atherosclerotic vascular disease; cholesterol; rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

J.M.M. has received honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Almirall, Amgen, Sanofi, Novartis, Daichi Sankyo and C.E. has received honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Almirall, Amgen, Novartis, Sanofi, Daichii Sankyo, Viatris.

Figures

Figure 1
Figure 1
Proportion of patients that achieve LDL-C targets and proportion of patients using lipid-lowering drugs in the SANTORINI study according to the presence of vascular disease. LDL-C: low-density lipoprotein cholesterol; PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitors. Figure created with data from reference [16].
Figure 2
Figure 2
Effect of rosuvastatin vs. placebo on main clinical outcomes in the JUPITER trial. Primary endpoint: myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina or cardiovascular death. MACE: cardiovascular death, myocardial infarction, or stroke. CVD: cardiovascular disease. HR: Hazard Ratio. 95% CI: 95% confidence interval. LDL-C: low-density lipoprotein cholesterol. Figure made with data from reference [39].
See this image and copyright information in PMC

References

    1. Deaths According to Cause. [(accessed on 11 March 2024)]. Statistics National Institute. Available online: https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=12....
    1. García González J.M. Contributions of cardiovascular mortality to Spanish life expectancy from 1980 to 2009. Rev. Esp. Cardiol. 2013;66:848–853. doi: 10.1016/j.recesp.2013.05.014. - DOI - PubMed
    1. Flores-Mateo G., Grau M., O’Flaherty M., Ramos R., Elosua R., Violan-Fors C., Quesada M., Martí R., Sala J., Marrugat J., et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988–2005. Rev. Esp. Cardiol. 2011;64:988–996. doi: 10.1016/j.recesp.2011.05.033. - DOI - PubMed
    1. Ford E.S., Ajani U.A., Croft J.B., Critchley J.A., Labarthe D.R., Kottke T.E., Giles W.H., Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N. Engl. J. Med. 2007;356:2388–2398. doi: 10.1056/NEJMsa053935. - DOI - PubMed
    1. Mulita F., Lampropoulos C., Kehagias D., Verras G.I., Tchabashvili L., Kaplanis C., Liolis E., Iliopoulos F., Perdikaris I., Kehagias I. Long-term nutritional deficiencies following sleeve gastrectomy: A 6-year single-centre retrospective study. Prz. Menopauzalny. 2021;20:170–176. doi: 10.5114/pm.2021.110954. - DOI - PMC - PubMed

LinkOut - more resources